Shanghai Kai Kai Industry Co Ltd A

Kaikai Industrial hit a limit-up on August 10, sealing the board for the third consecutive trading day. The stock closed at 14.27 yuan, up 10.02%, with over 40,000 lots locked in and a turnover of about 84.25 million yuan. Its latest market capitalization stands at 3.748 billion yuan. The company previously announced on the evening of August 6 that it authorized its wholly-owned subsidiary, Shanghai Leiyunshang Pharmaceutical West District Co., Ltd., to acquire a 60% stake held by minority shareholders in its controlled subsidiary, Shanghai Leixi Jingyi Supply Chain Management Co., Ltd., through a non-public agreement. The transaction price is set at 39.46 million yuan, below the appraised value of 47.386 million yuan. Kaikai Industrial stated that after the acquisition, it expects to add approximately 13.8 million yuan in annual net profit attributable to the parent company, helping to enhance profitability and improve shareholder returns.

Kaikai Industrial's wholly-owned subsidiary Leixi Company plans to use its own funds to acquire a 60% equity stake in its controlled subsidiary Leixi Jingyi, with a preliminary estimated price of approximately 47.39 million yuan. The final price will be determined based on the official appraisal value after filing with the state-owned assets authority. Upon completion of the transaction, Leixi Company's equity stake in Leixi Jingyi will increase from 40% to 100%, with no change to the scope of consolidated financial statements. Leixi Jingyi achieved operating revenue of 590 million yuan and net profit of 23.08 million yuan in 2025, becoming the core business of the company's 'Big Health' transformation. In the first quarter of 2026, Kaikai Industrial recorded revenue of 269 million yuan and net profit attributable to the parent company of 18.05 million yuan.

Kaikai Industrial disclosed its earnings forecast, expecting net profit attributable to owners of the parent for the first half of 2026 to be between 21.46 million yuan and 22.42 million yuan, a year-on-year increase of 81.85% to 89.98%. Net profit after deducting non-recurring items is expected to be between 1.92 million yuan and 2.88 million yuan, a year-on-year decline of 4.27% to 36.18%. The projected profit growth mainly stems from non-recurring gains. The company publicly listed and transferred its 11.11% stake in Nanjing Tianshi Software Technology Company through the Shanghai United Assets and Equity Exchange, with a transaction amount of 17.48 million yuan, which is expected to impact net profit attributable to the parent by approximately 11.9 million yuan. There was no comparable item in the same period last year. The company's main businesses include pharmaceutical distribution and services, as well as apparel wholesale and retail. During the reporting period, all main businesses advanced steadily with a stable operating trend.